All In Biotech

Drug Trial Radar · NCT03923725

A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,583 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,583

Actual

Start

Sep 1, 2020

Primary completion

Mar 15, 2024

Study completion Mar 15, 2024

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Mahidol Oxford Tropical Medicine Research Unit
First posted
Apr 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the ACTs artemether-lumefantrine+placebo (AL+PBO), artesunate-mefloquine+placebo (ASMQ+PBO) (with single-low dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria to assess and compare their efficacy, safety, tolerability.

Conditions

  • Plasmodium Falciparum Malaria (Uncomplicated)

Interventions

  • Artemether-lumefantrine+ Amodiaquine (AL+AQ)Drug

    AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children. The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days. AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days.

  • Artemether-lumefantrine + placebo (AL+PBO)Drug

    AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children. The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days. PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.

  • Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)Drug

    AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day. MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day. PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately. * 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day. * 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day.

  • Artesunate-mefloquine+placebo (AS-MQ+PBO)Drug

    AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day. MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day. PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 42 days Efficacy defined as PCR corrected adequate clinical and parasitological response (ACPR).Time frame: 42 days

Locations

8 sites in 8 countries. Site status is shown where the registry gives one.

  • Institut des Sciences et Techniques (INSTech)

    Bobo-Dioulasso, Burkina Faso

  • Kinshasa School of Public Health

    Kinshasa, Democratic Republic of the Congo

  • Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah

    Conakry, Guinea

  • Epicentre Niger

    Niamey, Niger

  • Centre for Malaria and Other Tropical Diseases (CEMTROD)

    Ilorin, Kwara State, Nigeria

  • College of Medicine and Health Sciences, University of Rwanda

    Kigali, Rwanda

  • National Institute For Medical Research (NIMR), Tanga Medical Research Centre

    Tanga, Tanzania

  • MRC Unit The Gambia at LSHTM

    Fajara, City of Banjul, The Gambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.